References

Epidemiology of follicular lymphoma

10.1016/j.hoc.2020.02.001 · 2020 · External reference

2016 US lymphoid malignancy statistics by World Health Organization subtypes

2016 · External reference

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

10.1182/blood-2005-06-2508 · 2006 · External reference

Follicular lymphoma: recent and emerging therapies, treatment strategies, and remaining unmet needs

10.1634/theoncologist.2019-0138 · 2019 · External reference

The impact of sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis

10.1016/j.clml.2022.06.014 · 2022 · External reference

Follicular lymphoma in the United States: first report of the national LymphoCare study

10.1200/jco.2008.18.1495 · 2009 · External reference

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

10.3324/haematol.2022.281421 · 2023 · External reference

A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)

10.1097/hs9.0000000000000745 · 2022 · External reference

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

10.1016/s2352-3026(22)00033-3 · 2022 · External reference

10.1007/s00277-020-04345-3

10.1007/s00277-020-04345-3 · 2021 · External reference

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi

10.1200/jco.20.02465 · 2021 · External reference

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

10.1182/blood.2020010263 · 2022 · External reference

Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

10.1016/j.annonc.2020.11.008 · 2021 · External reference

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

10.1038/s41408-021-00598-x · 2022 · External reference

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

10.1016/s0140-6736(12)61763-2 · 2013 · External reference

Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study

10.1200/jco.19.01073 · 2019 · External reference

First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study

10.1200/jco.18.00605 · 2019 · External reference

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

10.1200/jco.19.00010 · 2019 · External reference

Rituximab plus lenalidomide in advanced untreated follicular lymphoma

10.1056/nejmoa1805104 · 2018 · External reference

Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-Medicare analysis of elderly patients

10.2217/fon-2019-0660 · 2020 · External reference

Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States

10.1111/bjh.13399 · 2015 · External reference

Treatment patterns among elderly follicular lymphoma patients diagnosed between 2000 and 2011: an analysis of linked SEER-Medicare data [abstract 7563]

2017 · External reference

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

10.1182/blood-2013-11-531327 · 2014 · External reference

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

10.1038/s41408-020-00340-z · 2020 · External reference

Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study

10.1111/bjh.15149 · 2019 · External reference

Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study

10.1200/jco.2014.59.7534 · 2015 · External reference

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

10.3324/haematol.2018.209015 · 2019 · External reference

Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

10.1182/blood.2019000258 · 2019 · External reference

Trial-in-progress: randomized phase II trial in early relapsing or refractory follicular lymphoma (NCT#03269669): SWOG S1608 [abstract]

10.1182/blood-2021-146182 · 2021 · External reference

Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes

10.1002/cncr.31821 · 2019 · External reference

Impact on medical cost, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER-Medicare

10.1155/2012/978391 · 2012 · External reference

Standards should be applied in the prevention and handling of missing data for patient-centered outcomes research: a systematic review and expert consensus

10.1016/j.jclinepi.2013.08.013 · 2014 · External reference

Age differences in clinical trial understanding in non-Hodgkin lymphoma patients

10.1016/j.clml.2022.02.003 · 2022 · External reference